Admin Safety and pharmacokinetics of dolutegravir in HIV-positive pregnant women: a systematic review
| Author List |
|---|
| Andrew Hill |
| Polly Clayden |
| Claire Thorne |
| Rachel Christie |
| Rebecca Zash |
Abstract
The integrase strand transfer inhibitor (INSTI) dolutegravir (DTG) is recommended as an alternative first-line HIV treatment to efavirenz (EFV) in the current World Health Organization (WHO) consolidated antiretroviral (ARV) guidelines, and is widely recommended in other international treatment guidelines.
Published
Article Category
HIV Treatment
Article Type
Original research
Posted Date
29-03-2018
| File Name |
|---|
| 1522570199JVE-4-66.pdf |
 JVE-4-66-g001.gif |